Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Marzetti's stock drops 6.56% after Q3 sales decline and supply issues with Chick-fil-A sauce revealed

Market News
14 May 2026
PRNewsWire
View Source
Bearish
pluang ai news

Marzetti reported a 3.2% decline in Retail segment net sales for Q3 fiscal 2026, driven by a 5.6% drop in sales volume and weaker sales in the club channel. The company disclosed it had sold consumers about a year's supply of Chick-fil-A sauce, impacting current sales. Following this news, Marzetti's stock fell 6.56% on May 4, 2026. Pomerantz LLP has launched an investigation into potential securities fraud or unlawful practices by Marzetti and its officers.

More News

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Adventure & Dive Resort in Belize was ranked the #1 hotel in Central America and #15 globally in the 2026 Tripadvisor Travelers’ Choice Best of the Best Awards. This prestigious recognition is based on exceptional guest reviews and highlight...

Others
Neutral
1 hour ago
US government buys 10% stake in mining firms, signaling a new strategic investment trend.

US government buys 10% stake in mining firms, signaling a new strategic investment trend.

In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...

Market News
Bullish
1 hour ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...

Market News
Bullish
2 hours ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...

Market News
Bullish
2 hours ago
Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express, Inc. announced a regular quarterly cash dividend of $0.02 per share, payable on July 6, 2026, to shareholders of record as of June 23, 2026. This marks the company's 92nd consecutive quarterly dividend, with a total payout of $564....

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App